Keywords: Boehringer Ingelheim,, Pradaxa, Atrial fibrillation, Dabigatran, Warfarin, ACC

Boehringer’s anti-clotting drug Pradaxa added to ACC recommendations for treating irregular heartbeat

Article | 16 February 2011

Print This

The recently-approved drug dabigatran is recommended as an alternative to warfarin to help prevent dangerous blood clots in patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in